SuperworthEdesa Biotech EPS EDSA
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Dec 31, 2021
- −$8.12
- Latest quarter, Q1 FY22
- −$2.31
- Fiscal year 2021
- −$7.63
Edesa Biotech's earnings per share was −$8.12 over the twelve months to Dec 31, 2021.
In its latest quarter, Q1 FY22, it was −$2.31.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$7.63 | n/a |
| FY2020 | −$5.18 | n/a |
| FY2019 | −$4.90 | n/a |
| FY2018 | −$86.59 | n/a |
| FY2017 | −$145.32 | n/a |
| FY2016 | −$164.64 | n/a |
| FY2015 | −$105.84 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY22 | −$2.31 | n/a | −$8.12 | |
| Q4 FY21 | −$1.96 | n/a | −$7.63 | |
| Q3 FY21 | −$2.52 | n/a | −$7.21 | |
| Q2 FY21 | −$1.33 | n/a | −$6.09 | |
| Q1 FY21 | −$1.82 | n/a | −$5.95 | |
| Q4 FY20 | −$1.54 | n/a | −$5.18 | |
| Q3 FY20 | −$1.40 | n/a | −$4.55 | |
| Q2 FY20 | −$1.19 | n/a | −$5.25 | |
| Q1 FY20 | −$1.05 | n/a | −$5.18 | |
| Q4 FY19 | −$0.91 | n/a | −$4.90 | |
| Q3 FY19 | −$2.10 | n/a | −$12.81 | |
| Q2 FY19 | −$1.12 | n/a | −$11.62 |
Against its peers
Companies in Drug Manufacturers - General nearest Edesa Biotech's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EDSAEdesa Biotech | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Edesa Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.